Abstract: A Compton telescope for dose monitoring in hadron therapy is under development at IFIC. The system consists of three layers of LaBr3 crystals coupled to silicon photomulti-plier arrays. Na-22 sources have been successfully imaged reconstructing the data with an ML-EM code. Calibration and temperature stabilization are necessary for the prototype operation at low coincidence rates. A spatial resolution of 7.8 mm FWHM has been obtained in the first imaging tests.

Abstract: Cosmological analysis based on currently available observations are unable to rule out a sizeable coupling among the dark energy and dark matter fluids. We explore a variety of coupled dark matter-dark energy models, which satisfy cosmic microwave background constraints, in light of low redshift and near universe observations. We illustrate the phenomenology of different classes of dark coupling models, paying particular attention in distinguishing between effects that appear only on the expansion history and those that appear in the growth of structure. We find that while a broad class of dark coupling models are effectively models where general relativity (GR) is modified – and thus can be probed by a combination of tests for the expansion history and the growth of structure -, there is a class of dark coupling models where gravity is still GR, but the growth of perturbations is, in principle modified. While this effect is small in the specific models we have considered, one should bear in mind that an inconsistency between reconstructed expansion history and growth may not uniquely indicate deviations from GR. Our low redshift constraints arise from cosmic velocities, redshift space distortions and dark matter abundance in galaxy voids. We find that current data constrain the dimensionless coupling to be vertical bar xi vertical bar < 0.2, but prospects from forthcoming data are for a significant improvement. Future, precise measurements of the Hubble constant, combined with high-precision constraints on the growth of structure, could provide the key to rule out dark coupling models which survive other tests. We shall exploit as well weak equivalence principle violation arguments, which have the potential to highly disfavour a broad family of coupled models.

Abstract: The observation of space-time variations in fundamental constants would provide strong evidence for the existence of new light degrees of freedom in the theory of Nature. Robustly constraining such scenarios requires exploiting observations that span different scales and probe the state of the Universe at different epochs. In the context of cosmology, both the cosmic microwave background and the Lyman-a forest have proven to be powerful tools capable of constraining variations in electromagnetism, however at the moment there do not exist cosmological probes capable of bridging the gap between recombination and reionization. In the near future, radio telescopes will attempt to measure the 21 cm transition of neutral hydrogen during the epochs of reionization and the cosmic dawn (and potentially the tail end of the dark ages); being inherently sensitive to electromagnetic phenomena, these experiments will offer a unique perspective on space-time variations of the fine-structure constant and the electron mass. We show here that large variations in these fundamental constants would produce features on the 21 cm power spectrum that may be distinguishable from astrophysical uncertainties. Furthermore, we forecast the sensitivity for the Square Kilometer Array, and show that the 21 cm power spectrum may be able to constrain variations at the level of O(10(-3)).

Abstract: Future dedicated radio interferometers, including HERA and SKA, are very promising tools that aim to study the epoch of reionization and beyond via measurements of the 21 cm signal from neutral hydrogen. Dark matter (DM) annihilations into charged particles change the thermal history of the Universe and, as a consequence, affect the 21 cm signal. Accurately predicting the effect of DM strongly relies on the modeling of annihilations inside halos. In this work, we use up-to-date computations of the energy deposition rates by the products from DM annihilations, a proper treatment of the contribution from DM annihilations in halos, as well as values of the annihilation cross section allowed by the most recent cosmological measurements from the Planck satellite. Given current uncertainties on the description of the astrophysical processes driving the epochs of reionization, X-ray heating and Lyman-alpha pumping, we find that disentangling DM signatures from purely astrophysical effects, related to early-time star formation processes or late-time galaxy X-ray emissions, will be a challenging task. We conclude that only annihilations of DM particles with masses of similar to 100 MeV, could leave an unambiguous imprint on the 21 cm signal and, in particular, on the 21cm power spectrum. This is in contrast to previous, more optimistic results in the literature, which have claimed that strong signatures might also be present even for much higher DM masses. Additional measurements of the 21cm signal at different cosmic epochs will be crucial in order to break the strong parameter degeneracies between DM annihilations and astrophysical effects and undoubtedly single out a DM imprint for masses different from similar to 100 MeV.

Abstract: PurposeA joint working group was created by the American Association of Physicists in Medicine (AAPM), the European Society for Radiotherapy and Oncology (ESTRO), and the Australasian Brachytherapy Group (ABG) with the charge, among others, to develop a set of well-defined test case plans and perform calculations and comparisons with model-based dose calculation algorithms (MBDCAs). Its main goal is to facilitate a smooth transition from the AAPM Task Group No. 43 (TG-43) dose calculation formalism, widely being used in clinical practice for brachytherapy, to the one proposed by Task Group No. 186 (TG-186) for MBDCAs. To do so, in this work a hypothetical, generic high-dose rate (HDR) Ir-192 shielded applicator has been designed and benchmarked. MethodsA generic HDR Ir-192 shielded applicator was designed based on three commercially available gynecological applicators as well as a virtual cubic water phantom that can be imported into any DICOM-RT compatible treatment planning system (TPS). The absorbed dose distribution around the applicator with the TG-186 Ir-192 source located at one dwell position at its center was computed using two commercial TPSs incorporating MBDCAs (Oncentra((R)) Brachy with Advanced Collapsed-cone Engine, ACE, and BrachyVision ACUROS) and state-of-the-art Monte Carlo (MC) codes, including ALGEBRA, BrachyDose, egs_brachy, Geant4, MCNP6, and Penelope2008. TPS-based volumetric dose distributions for the previously reported source centered in water and source displaced test cases, and the new source centered in applicator test case, were analyzed here using the MCNP6 dose distribution as a reference. Volumetric dose comparisons of TPS results against results for the other MC codes were also performed. Distributions of local and global dose difference ratios are reported. ResultsThe local dose differences among MC codes are comparable to the statistical uncertainties of the reference datasets for the source centered in water and source displaced test cases and for the clinically relevant part of the unshielded volume in the source centered in applicator case. Larger local differences appear in the shielded volume or at large distances. Considering clinically relevant regions, global dose differences are smaller than the local ones. The most disadvantageous case for the MBDCAs is the one including the shielded applicator. In this case, ACUROS agrees with MC within [-4.2%, +4.2%] for the majority of voxels (95%) while presenting dose differences within [-0.12%, +0.12%] of the dose at a clinically relevant reference point. For ACE, 95% of the total volume presents differences with respect to MC in the range [-1.7%, +0.4%] of the dose at the reference point. ConclusionsThe combination of the generic source and generic shielded applicator, together with the previously developed test cases and reference datasets (available in the Brachytherapy Source Registry), lay a solid foundation in supporting uniform commissioning procedures and direct comparisons among treatment planning systems for HDR Ir-192 brachytherapy.